Weight loss drug Ozempic may now smash these FTSE 100 stocks

The new breed of weight loss treatments may be a big win for the pharmaceutical sector but other FTSE 100 stocks may rue the day.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Female Doctor In White Coat Having Meeting With Woman Patient In Office

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Even major FTSE 100 stocks aren’t immune to Black Swan events and one of them could be heading their way in the shape of GLP-1 weight loss drugs like Ozempic and Wegovy.

These are the two best known prescription medications for people living with obesity. Their early success has put a rocket under the shares of Danish pharmaceutical company Novo Nordisk, now Europe’s biggest company. Other sectors won’t come out of this so well.

GLP-1 drugs were developed to treat type II diabetes, by helping users reduce blood sugar levels. They suppress appetite by telling the brain you’re full. They also slow digestion, so food takes longer to leave the body. It’s a huge step forward.

Unforeseen consequences

However, it may be a huge step backwards for FTSE 100 companies selling addictive products like sugar, alcohol and tobacco, which could experience a sharp drop in demand among their most avid users.

If I was the CEO of British American Tobacco, Imperial Brands and spirits maker Diageo, I’d be worried. We all know how hard it is to quit smoking. Around 30% of smokers try every year, but few succeed at the first attempt. 

Giving up drinking isn’t easy either. Dry January has made some inroads and younger drinkers are boozing less. There are an estimated 600,000 dependent drinkers in the UK, but less than one in five receive treatment. Now those who want to kick or cut back have another weapon in their armoury. Diageo’s biggest market is the US. Ozempic et al will be huge over there.

There could be a snowball effect too. As more people stop drinking, it will become easier for politicians to crack down on those who do. I’m keen to add Diageo to my portfolio, taking advantage of a 15% drop in its share price over the last year. Now there’s a new threat I hadn’t considered.

Could be a game changer

I did buy consumer goods giant Unilever recently, as its shares looked nicely priced. However, as well as soap and shampoo, Unilever owns Ben & Jerry’s, and we all know how addictive that is. Plus it owns Hellmann’s, Knorr, Magnum and Wall’s.

Associated British Foods could also be at risk. Its grocery brands include Allinson’s, Allied Bakeries, Blue Dragon, Patak’s, Kingsmill, Jordans, Mazola and Silver Spoon. ABF’s sugar business has the capacity to produce some 4.5m tonnes of sugar annually. Will the world be eating as much of it in future? At least ABF has Primark. All those newly slim shoppers will need a new wardrobe.

What about Tesco, Sainsbury’s, Ocado, Marks & Spencer Group? For that matter, what about The Restaurant Group? Greggs?

These are early days. Not everybody will be taking Ozempic. But with the Health Survey for England 2021 estimating 25.9% of adults in England are obese and a further 37.9% are overweight, many will be tempted. It’s something investors in FTSE 100 food, alcohol and tobacco stocks didn’t have to consider a few months ago.

Fortunately, there are plenty of other Footsie stocks that won’t be affected, whatever happens. There are plenty that I’m bullish on right now, too many to mention them all here of course. Make no mistake, I still believe buying shares in quality companies is the best route to wealth generation available to us all!

Harvey Jones has positions in Unilever Plc. The Motley Fool UK has recommended Associated British Foods Plc, British American Tobacco P.l.c., Diageo Plc, Imperial Brands Plc, J Sainsbury Plc, Novo Nordisk, Ocado Group Plc, Tesco Plc, and Unilever Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

How much do you need in an ISA to target £1,000 of monthly passive income?

Dr James Fox outlines the strategy for building passive income in an ISA and one stock that could help propel…

Read more »

Investing Articles

Will the S&P 500 crash in 2026?

The S&P 500 delivered impressive gains in 2025, but valuations are now running high. Are US stocks stretched to breaking…

Read more »

Teenage boy is walking back from the shop with his grandparent. He is carrying the shopping bag and they are linking arms.
Investing Articles

How much do you need in a SIPP to generate a brilliant second income of £2,000 a month?

Harvey Jones crunches the numbers to show how investors can generate a high and rising passive income from a portfolio…

Read more »

Investing Articles

Will Lloyds shares rise 76% again in 2026?

What needs to go right for Lloyds shares to post another 76% rise? Our Foolish author dives into what might…

Read more »

Investing Articles

How much passive income will I get from investing £10,000 in an ISA for 10 years?

Harvey Jones shows how he plans to boost the amount of passive income he gets when he retires, from FTSE…

Read more »

Investing Articles

Down 34% in 2025 — but could this be one of the UK’s top growth stocks for 2026?

With clarity over research funding on the horizon, could Judges Scientific be one of the UK’s best growth stocks to…

Read more »

piggy bank, searching with binoculars
Investing Articles

Can the rampant Barclays share price beat Lloyds in 2026?

Harvey Jones says the Barclays share price was neck and neck with Lloyds over the last year, and checks out…

Read more »

Investing Articles

Here’s how Rolls-Royce shares could hit £25 in 2026

If Rolls-Royce shares continue their recent performance, then £25 might be on the cards for 2026. Let's take a look…

Read more »